Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Shutters Yokkaichi Plant
December 6, 2013
- M3 to Make Mediscience Planning Its Wholly Owned Subsidiary
December 6, 2013
- Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated
December 5, 2013
- Takeda to Market Teva’s Multiple Sclerosis Treatment in Japan
December 5, 2013
- Sawai President Requests Cautious Discussions on Generic Prices, Shows Confidence in Surviving
December 5, 2013
- “Big Gap” Remains to Reach 5-Year Profit Target: Astellas Pres.
December 5, 2013
- DSP, Healios Tie Up, Aim to Launch iPS Products in 2018
December 4, 2013
- Ono Joins SGLT-2 Inhibitor Battle via Copromotion Deal with AstraZeneca
December 4, 2013
- Eisai Shakes Up R&D Organization, Paring 130 Jobs in US, Europe
December 4, 2013
- Eisai to Transfer Business Operations at Misato Plant to Bushu Pharmaceuticals
December 4, 2013
- Bayer HealthCare Files Eylea for mCNV in Japan
December 4, 2013
- Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later
December 3, 2013
- Takeda Ready to Welcome Foreign Exec with Open Arms as Company Leader
December 3, 2013
- Japan Gardasil Sales Dive 49.6% in January-September
December 3, 2013
- Merck to Shed 200 Jobs in Japan by 2015
December 3, 2013
- Eisai to Offer Voluntary Retirement Program in Japan
December 3, 2013
- Takeda President Calls GSK Weber Competitive Global Talent, Pushes Globalization
December 2, 2013
- Eisai Files for Approval of Pariet for Preventing Recurrent Ulcers during Aspirin Therapy
December 2, 2013
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
- AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada
November 29, 2013
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…